TITLE

Site relationship management: Sponsors help sites be more productive

PUB. DATE
July 2008
SOURCE
Clinical Trials Administrator;Jul2008, Vol. 6 Issue 7, p73
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article looks at the site relationship management (SRM) and investigator relationship management (IRM) initiatives by pharmaceutical companies to improve relationships with clinical trial sites. It mentions some of the common goals of trial sponsors including helping sites function better and increasing investigator retention. The role of the clinical research assistant (CRA) should change to successfully implement SRM initiatives, according to Beth Harper of Clinical Performance Partners.
ACCESSION #
32682820

 

Related Articles

  • PhRMA updates principles for conduct of clinical trials.  // Pharmacy Today;Aug2004, Vol. 10 Issue 8, p3 

    The Pharmaceutical Research and Manufacturers of America (PhRMA) has adopted a set of updated principles for conducting and reporting clinical trials that commit drug companies to the timely communication of all meaningful results, whether those results are positive or negative. PhRMA stated...

  • Clinical Trials and CROs in the 21st Century. Hindin, Toby Jane // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p12 

    The clinical research oversight (CRO) industry has reached a new stage of growth in clinical trials. There are now more than one thousand CRO with the largest number existing in Europe, followed by North America and Japan. While research and development costs are skyrocketing, product approvals...

  • Nonpatentable drugs and the cost of our ignorance. Calon, Frédéric // CMAJ: Canadian Medical Association Journal;2/14/2006, Vol. 174 Issue 4, p483 

    The article comments on the issue of funding for the pharmaceutical industry's randomized controlled clinical trials (RCT). Potential efficacy of drugs based on patentability and nonpatentability is questioned. The viability of investing in the clinical study for nonpatented drugs is also discussed.

  • A New Colonialism? – Conducting Clinical Trials in India. Nundy, Samiran; Gulhati, Chandra M. // New England Journal of Medicine;4/21/2005, Vol. 352 Issue 16, p1633 

    The article reports that the government of India in January 2005 rendered a new rule which allows foreign pharmaceutical companies to conduct trials of new drugs in India at the same time that trials of the same phase are being conducted in other countries. This new rule replaces the directive...

  • Waxman scolds PhRMA firms for ignoring patient resource. Dickinson, James G. // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p17 

    Reports on the complaint issued by U.S. Rep. Henry Waxman to the Pharmaceutical Research and Manufacturers of America about the failure of companies to report their cancer clinical trials, as required by law. Failure of the pharmaceutical industry to report trials on a web site as required;...

  • e Showcase.  // Applied Clinical Trials;Mar2004, Vol. 13 Issue 3, p76 

    Provides information about business enterprises related to clinical medicine research and the pharmaceutical industry in the U.S. Algorithe Pharma Inc.; Baxter Pharmaceutical Solutions LLC; Bio-Imaging Technologies Inc.

  • Tools for Clinical Trials Professionals.  // Applied Clinical Trials;Mar2006, Vol. 15 Issue 3, p28 

    No abstract available.

  • One World, One Voice. Delagneau, Bruno // Pharmaceutical Executive;Jul2004, Vol. 24 Issue 7, p76 

    Discusses the benefits to the pharmaceutical industry of the regulatory harmonization that started in the United States in the 1990s. Provision for companies to limit the length and expense of global clinical development programs by conducting large clinical studies at key centers worldwide;...

  • POLL: Industry Should Focus on Drug Safety.  // Applied Clinical Trials;Oct2005, Vol. 14 Issue 10, p18 

    Reports on results of "Applied Clinical Trials" magazine's online poll about issues in which the pharmaceutical industry should focus on to regain public trust. Drug safety; Drug promotion; Global supply chain integrity; Regulatory climate; Open clinical trial registries.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics